{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T09:20:16Z","timestamp":1788254416172,"version":"build-2803163510"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"crossref","award":["KAKENHI Grant-in-Aid for Scientific Research (A) (grant numbers 19H00968 and 23H00357)"],"award-info":[{"award-number":["KAKENHI Grant-in-Aid for Scientific Research (A) (grant numbers 19H00968 and 23H00357)"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Molecular-targeted therapies require biomarker-driven evaluation to optimize precision oncology strategies; however, translational models integrating clinical outcomes with mechanistic biomarkers are limited. Canine urothelial carcinoma shares molecular features with human muscle-invasive bladder cancer, including activation of VEGFR signaling, providing a valuable comparative oncology platform. Sorafenib is a multi-kinase inhibitor targeting VEGFRs, PDGFR\u03b2, BRAF, and related pathways, but its therapeutic mechanisms and clinical benefit in urothelial carcinoma remain incompletely understood. In this study, 43 dogs with naturally occurring urothelial carcinoma received first-line sorafenib and piroxicam therapy. The overall response rate was 62.8%, with median progression-free and overall survival of 175 (range, 31\u2013665) and 407 (range, 103\u20131,723) days, respectively. The results exceeded outcomes in historical controls treated with piroxicam alone. Treatment was generally well tolerated, with only three grade 3 adverse events and no grade 4\u20135 toxicities. Biomarker analyses revealed that treatment-induced hypertension and high tumor\n                    <jats:italic>CX3CL1<\/jats:italic>\n                    mRNA expression were independently associated with improved overall survival, suggesting that effective VEGFR pathway inhibition and modulation of the tumor immune microenvironment contribute to clinical benefit. These findings support sorafenib-based therapy as a promising strategy for canine urothelial carcinoma and highlight the translational potential of biomarker-driven VEGFR-targeted approaches in precision oncology.\n                  <\/jats:p>","DOI":"10.1038\/s41598-026-64955-1","type":"journal-article","created":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T09:02:18Z","timestamp":1788253338000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Sorafenib\/piroxicam therapy with biomarker-defined survival benefit in canine muscle-invasive urothelial carcinoma"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1413-1258","authenticated-orcid":false,"given":"Shingo","family":"Maeda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shohei","family":"Yokota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mao","family":"Komori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuko","family":"Goto-Koshino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James K.","family":"Chambers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuyuki","family":"Uchida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohiro","family":"Yonezawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuyuki","family":"Momoi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,1]]},"reference":[{"key":"64955_CR1","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1002\/ijc.31937","volume":"144","author":"J Ferlay","year":"2019","unstructured":"Ferlay, J. et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int. J. Cancer. 144, 1941\u20131953 (2019).","journal-title":"Int. J. Cancer"},{"key":"64955_CR2","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/S0140-6736(09)60491-8","volume":"374","author":"DS Kaufman","year":"2009","unstructured":"Kaufman, D. S., Shipley, W. U. & Feldman, A. S. Bladder cancer. Lancet 374, 239\u2013249 (2009).","journal-title":"Lancet"},{"key":"64955_CR3","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1200\/JCO.2011.37.3571","volume":"30","author":"M De Santis","year":"2012","unstructured":"De Santis, M. et al. Randomized phase II\/III trial assessing gemcitabine\/carboplatin and methotrexate\/carboplatin\/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986. J. Clin. Oncol. 30, 191\u2013199 (2012).","journal-title":"J. Clin. Oncol."},{"key":"64955_CR4","doi-asserted-by":"publisher","first-page":"4602","DOI":"10.1200\/JCO.2005.07.757","volume":"23","author":"H von der Maase","year":"2005","unstructured":"von der Maase, H. et al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J. Clin. Oncol. 23, 4602\u20134608 (2005).","journal-title":"J. Clin. Oncol."},{"key":"64955_CR5","doi-asserted-by":"publisher","first-page":"3129","DOI":"10.1158\/1535-7163.MCT-08-0013","volume":"7","author":"SM Wilhelm","year":"2008","unstructured":"Wilhelm, S. M. et al. Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol. Cancer Ther. 7, 3129\u20133140 (2008).","journal-title":"Mol. Cancer Ther."},{"key":"64955_CR6","doi-asserted-by":"publisher","first-page":"e0134346","DOI":"10.1371\/journal.pone.0134346","volume":"10","author":"CX Pan","year":"2015","unstructured":"Pan, C. X. et al. Development and characterization of bladder cancer patient-derived xenografts for molecularly guided targeted therapy. PLoS ONE 10, e0134346 (2015).","journal-title":"PLoS ONE"},{"key":"64955_CR7","doi-asserted-by":"publisher","first-page":"1690","DOI":"10.1111\/j.1476-5381.2010.00838.x","volume":"160","author":"A Rose","year":"2010","unstructured":"Rose, A. et al. Stimulatory effects of the multi-kinase inhibitor sorafenib on human bladder cancer cells. Br. J. Pharmacol. 160, 1690\u20131698 (2010).","journal-title":"Br. J. Pharmacol."},{"key":"64955_CR8","doi-asserted-by":"publisher","first-page":"395","DOI":"10.18632\/oncoscience.147","volume":"2","author":"C Amantini","year":"2015","unstructured":"Amantini, C. et al. Sorafenib induces cathepsin B-mediated apoptosis of bladder cancer cells by regulating the Akt\/PTEN pathway. The Akt inhibitor, perifosine, enhances the sorafenib-induced cytotoxicity against bladder cancer cells. Oncoscience 2, 395\u2013409 (2015).","journal-title":"Oncoscience"},{"key":"64955_CR9","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1111\/bju.12437","volume":"113","author":"S Krege","year":"2014","unstructured":"Krege, S. et al. Prospective randomized double-blind multicentre phase II study comparing gemcitabine and cisplatin plus sorafenib chemotherapy with gemcitabine and cisplatin plus placebo in locally advanced and\/or metastasized urothelial cancer: SUSE (AUO-AB 31\/05). BJU Int. 113, 429\u2013436 (2014).","journal-title":"BJU Int."},{"key":"64955_CR10","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1007\/s10637-010-9408-4","volume":"29","author":"SS Sridhar","year":"2011","unstructured":"Sridhar, S. S. et al. A phase II trial of sorafenib in first-line metastatic urothelial cancer: a study of the PMH Phase II Consortium. Invest. New. Drugs. 29, 1045\u20131049 (2011).","journal-title":"Invest. New. Drugs"},{"key":"64955_CR11","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1634\/theoncologist.2018-0795","volume":"24","author":"CH Shah","year":"2019","unstructured":"Shah, C. H. et al. Safety and activity of sorafenib in addition to vinflunine in post-platinum metastatic urothelial carcinoma (vinsor): Phase I trial. Oncologist 24, 745-e213 (2019).","journal-title":"Oncologist"},{"key":"64955_CR12","doi-asserted-by":"publisher","first-page":"6589529","DOI":"10.1155\/2017\/6589529","volume":"2017","author":"CM Fulkerson","year":"2017","unstructured":"Fulkerson, C. M., Dhawan, D., Ratliff, T. L., Hahn, N. M. & Knapp, D. W. Naturally occurring canine invasive urinary bladder cancer: A complementary animal model to improve the success rate in human clinical trials of new cancer drugs. Int. J. Genomics 2017, 6589529 (2017).","journal-title":"Int. J. Genomics"},{"key":"64955_CR13","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/S1078-1439(99)00006-X","volume":"5","author":"DW Knapp","year":"2000","unstructured":"Knapp, D. W. et al. Naturally-occurring canine transitional cell carcinoma of the urinary bladder A relevant model of human invasive bladder cancer. Urol. Oncol. 5, 47\u201359 (2000).","journal-title":"Urol. Oncol."},{"key":"64955_CR14","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1093\/ilar\/ilu018","volume":"55","author":"DW Knapp","year":"2014","unstructured":"Knapp, D. W. et al. Urinary bladder cancer in dogs, a naturally occurring model for cancer biology and drug development. ILAR J. 55, 100\u2013118 (2014).","journal-title":"ILAR J."},{"key":"64955_CR15","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0136688","volume":"10","author":"D Dhawan","year":"2015","unstructured":"Dhawan, D. et al. Comparative gene expression analyses identify luminal and basal subtypes of canine invasive urothelial carcinoma that mimic patterns in human invasive bladder cancer. PLoS One 10, e0136688 (2015).","journal-title":"PLoS One"},{"key":"64955_CR16","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-018-4409-3","volume":"18","author":"S Maeda","year":"2018","unstructured":"Maeda, S. et al. Comprehensive gene expression analysis of canine invasive urothelial bladder carcinoma by RNA-Seq. BMC Cancer 18, 472 (2018).","journal-title":"BMC Cancer"},{"key":"64955_CR17","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgen.1007571","volume":"14","author":"D Dhawan","year":"2018","unstructured":"Dhawan, D., Hahn, N. M., Ramos-Vara, J. A. & Knapp, D. W. Naturally-occurring canine invasive urothelial carcinoma harbors luminal and basal transcriptional subtypes found in human muscle invasive bladder cancer. PLoS Genet. 14, e1007571 (2018).","journal-title":"PLoS Genet."},{"key":"64955_CR18","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-020-06737-0","volume":"20","author":"HG Parker","year":"2020","unstructured":"Parker, H. G. et al. RNAseq expression patterns of canine invasive urothelial carcinoma reveal two distinct tumor clusters and shared regions of dysregulation with human bladder tumors. BMC Cancer 20, 251 (2020).","journal-title":"BMC Cancer"},{"key":"64955_CR19","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0144170","volume":"10","author":"H Mochizuki","year":"2015","unstructured":"Mochizuki, H., Shapiro, S. G. & Breen, M. Detection of BRAF mutation in urine DNA as a molecular diagnostic for canine urothelial and prostatic carcinoma. PLoS One 10, e0144170 (2015).","journal-title":"PLoS One"},{"key":"64955_CR20","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1177\/10406387221146247","volume":"35","author":"LC Setyo","year":"2023","unstructured":"Setyo, L. C., Donahoe, S. L., Shearer, P. L., Wang, P. & Krockenberger, M. B. Immunohistochemical analysis of expression of VEGFR2, KIT, PDGFR-beta, and CDK4 in canine urothelial carcinoma. J. Vet. Diagn. Invest. 35, 109\u2013115 (2023).","journal-title":"J. Vet. Diagn. Invest."},{"key":"64955_CR21","doi-asserted-by":"publisher","first-page":"E117","DOI":"10.1111\/vco.12344","volume":"16","author":"L Walters","year":"2018","unstructured":"Walters, L., Martin, O., Price, J. & Sula, M. M. Expression of receptor tyrosine kinase targets PDGFR-beta, VEGFR2 and KIT in canine transitional cell carcinoma. Vet. Comp. Oncol. 16, E117\u2013E122 (2018).","journal-title":"Vet. Comp. Oncol."},{"key":"64955_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.vetimm.2025.111019","volume":"290","author":"S Yokota","year":"2025","unstructured":"Yokota, S. et al. Sorafenib inhibits myeloid-derived suppressor cell infiltration in canine transitional cell carcinoma. Vet. Immunol. Immunopathol. 290, 111019 (2025).","journal-title":"Vet. Immunol. Immunopathol."},{"key":"64955_CR23","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1292\/jvms.21-0478","volume":"84","author":"S Yokota","year":"2022","unstructured":"Yokota, S., Yonezawa, T., Momoi, Y. & Maeda, S. Sorafenib inhibits tumor cell growth and angiogenesis in canine transitional cell carcinoma. J. Vet. Med. Sci. 84, 666\u2013674 (2022).","journal-title":"J. Vet. Med. Sci."},{"key":"64955_CR24","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.tvjl.2015.01.017","volume":"205","author":"CM Fulkerson","year":"2015","unstructured":"Fulkerson, C. M. & Knapp, D. W. Management of transitional cell carcinoma of the urinary bladder in dogs: a review. Vet. J. 205, 217\u2013225 (2015).","journal-title":"Vet. J."},{"key":"64955_CR25","volume-title":"TNM Classification of Tumours in Domestic Animals","author":"LN Owen","year":"1980","unstructured":"Owen, L. N. TNM Classification of Tumours in Domestic Animals (World Health Organization (WHO), 1980)."},{"key":"64955_CR26","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-04229-0","volume":"12","author":"S Maeda","year":"2022","unstructured":"Maeda, S. et al. Lapatinib as first-line treatment for muscle-invasive urothelial carcinoma in dogs. Sci. Rep. 12, 4 (2022).","journal-title":"Sci. Rep."},{"key":"64955_CR27","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1111\/jch.12273","volume":"16","author":"Y Li","year":"2014","unstructured":"Li, Y. et al. Incidence and risk of sorafenib-induced hypertension: a systematic review and meta-analysis. J. Clin. Hypertens. (Greenwich). 16, 177\u2013185 (2014).","journal-title":"J. Clin. Hypertens. (Greenwich)"},{"key":"64955_CR28","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1080\/17474124.2017.1264874","volume":"11","author":"O Abdel-Rahman","year":"2017","unstructured":"Abdel-Rahman, O. & Lamarca, A. Development of sorafenib-related side effects in patients diagnosed with advanced hepatocellular carcinoma treated with sorafenib: a systematic-review and meta-analysis of the impact on survival. Expert Rev. Gastroenterol. Hepatol. 11, 75\u201383 (2017).","journal-title":"Expert Rev. Gastroenterol. Hepatol."},{"key":"64955_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.vetimm.2024.110716","volume":"269","author":"S Yokota","year":"2024","unstructured":"Yokota, S., Yonezawa, T., Momoi, Y. & Maeda, S. Myeloid derived suppressor cells in peripheral blood can be a prognostic factor in canine transitional cell carcinoma. Vet. Immunol. Immunopathol. 269, 110716 (2024).","journal-title":"Vet. Immunol. Immunopathol."},{"key":"64955_CR30","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.2460\/javma.231.7.1056","volume":"231","author":"SN Greene","year":"2007","unstructured":"Greene, S. N., Lucroy, M. D., Greenberg, C. B., Bonney, P. L. & Knapp, D. W. Evaluation of cisplatin administered with piroxicam in dogs with transitional cell carcinoma of the urinary bladder. J. Am. Vet. Med. Assoc. 231, 1056\u20131060 (2007).","journal-title":"J. Am. Vet. Med. Assoc."},{"key":"64955_CR31","first-page":"906","volume":"9","author":"CJ Henry","year":"2003","unstructured":"Henry, C. J. et al. Clinical evaluation of mitoxantrone and piroxicam in a canine model of human invasive urinary bladder carcinoma. Clin. Cancer Res. 9, 906\u2013911 (2003).","journal-title":"Clin. Cancer Res."},{"key":"64955_CR32","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1111\/jvim.12013","volume":"27","author":"DW Knapp","year":"2013","unstructured":"Knapp, D. W. et al. Randomized trial of cisplatin versus firocoxib versus cisplatin\/firocoxib in dogs with transitional cell carcinoma of the urinary bladder. J. Vet. Intern. Med. 27, 126\u2013133 (2013).","journal-title":"J. Vet. Intern. Med."},{"key":"64955_CR33","first-page":"183","volume":"2","author":"SI Mohammed","year":"2003","unstructured":"Mohammed, S. I. et al. Effects of the cyclooxygenase inhibitor, piroxicam, in combination with chemotherapy on tumor response, apoptosis, and angiogenesis in a canine model of human invasive urinary bladder cancer. Mol. Cancer Ther. 2, 183\u2013188 (2003).","journal-title":"Mol. Cancer Ther."},{"key":"64955_CR34","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1111\/vco.12286","volume":"15","author":"SJ Marvel","year":"2017","unstructured":"Marvel, S. J., Seguin, B., Dailey, D. D. & Thamm, D. H. Clinical outcome of partial cystectomy for transitional cell carcinoma of the canine bladder. Vet. Comp. Oncol. 15, 1417\u20131427 (2017).","journal-title":"Vet. Comp. Oncol."},{"key":"64955_CR35","first-page":"73","volume":"56","author":"K Saeki","year":"2015","unstructured":"Saeki, K., Fujita, A., Fujita, N., Nakagawa, T. & Nishimura, R. Total cystectomy and subsequent urinary diversion to the prepuce or vagina in dogs with transitional cell carcinoma of the trigone area: a report of 10 cases (2005\u20132011). Can. Vet. J. 56, 73\u201380 (2015).","journal-title":"Can. Vet. J."},{"key":"64955_CR36","doi-asserted-by":"publisher","first-page":"2177","DOI":"10.1158\/1535-7163.MCT-20-0893","volume":"20","author":"P Rossman","year":"2021","unstructured":"Rossman, P. et al. Phase I\/II trial of vemurafenib in dogs with naturally occurring, BRAF-mutated urothelial carcinoma. Mol. Cancer Ther. 20, 2177\u20132188 (2021).","journal-title":"Mol. Cancer Ther."},{"key":"64955_CR37","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1158\/2326-6066.CIR-18-0751","volume":"7","author":"S Maeda","year":"2019","unstructured":"Maeda, S., Murakami, K., Inoue, A., Yonezawa, T. & Matsuki, N. CCR4 blockade depletes regulatory T cells and prolongs survival in a canine model of bladder cancer. Cancer Immunol. Res. 7, 1175\u20131187 (2019).","journal-title":"Cancer Immunol. Res."},{"key":"64955_CR38","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1292\/jvms.23-0204","volume":"85","author":"S Maeda","year":"2023","unstructured":"Maeda, S. Second era of molecular-targeted cancer therapies in dogs. J. Vet. Med. Sci. 85, 790\u2013798 (2023).","journal-title":"J. Vet. Med. Sci."},{"key":"64955_CR39","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1007\/s11912-022-01224-0","volume":"24","author":"N Camarda","year":"2022","unstructured":"Camarda, N., Travers, R., Yang, V. K., London, C. & Jaffe, I. Z. VEGF receptor inhibitor-induced hypertension: emerging mechanisms and clinical implications. Curr. Oncol. Rep. 24, 463\u2013474 (2022).","journal-title":"Curr. Oncol. Rep."},{"key":"64955_CR40","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.00978","volume":"9","author":"J Yang","year":"2018","unstructured":"Yang, J., Yan, J. & Liu, B. Targeting VEGF\/VEGFR to modulate antitumor immunity. Front. Immunol. 9, 978 (2018).","journal-title":"Front. Immunol."},{"key":"64955_CR41","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-64832-5","volume":"10","author":"R Yoshitake","year":"2020","unstructured":"Yoshitake, R. et al. Aberrant expression of the COX2\/PGE2 axis is induced by activation of the RAF\/MEK\/ERK pathway in BRAF(V595E) canine urothelial carcinoma. Sci. Rep. 10, 7826 (2020).","journal-title":"Sci. Rep."},{"key":"64955_CR42","unstructured":"Maeda, S. et al.\u00a0BRAF(V595E) mutation associates CCL17 expression and regulatory T cell recruitment in urothelial carcinoma of dogs. Vet. Pathol. 300985820967449 (2020)."},{"key":"64955_CR43","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003731","author":"S Maeda","year":"2022","unstructured":"Maeda, S. et al. Anti-CCR4 treatment depletes regulatory T cells and leads to clinical activity in a canine model of advanced prostate cancer. J. Immunother. Cancer https:\/\/doi.org\/10.1136\/jitc-2021-003731 (2022).","journal-title":"J. Immunother. Cancer"},{"key":"64955_CR44","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1177\/0300985819879445","volume":"57","author":"K Sakai","year":"2020","unstructured":"Sakai, K. et al. ErbB2 copy number aberration in canine urothelial carcinoma detected by a digital polymerase chain reaction assay. Vet. Pathol. 57, 56\u201365 (2020).","journal-title":"Vet. Pathol."},{"key":"64955_CR45","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1177\/0300985818817024","volume":"56","author":"M Tsuboi","year":"2019","unstructured":"Tsuboi, M. et al. Assessment of HER2 expression in canine urothelial carcinoma of the urinary bladder. Vet. Pathol. 56, 369\u2013376 (2019).","journal-title":"Vet. Pathol."},{"key":"64955_CR46","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.tvjl.2017.12.008","volume":"232","author":"SI Honkisz","year":"2018","unstructured":"Honkisz, S. I., Naughton, J. F., Weng, H. Y., Fourez, L. M. & Knapp, D. W. Evaluation of two-dimensional ultrasonography and computed tomography in the mapping and measuring of canine urinary bladder tumors. Vet. J. 232, 23\u201326 (2018).","journal-title":"Vet. J."},{"key":"64955_CR47","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.2460\/ajvr.73.12.1919","volume":"73","author":"JF Naughton","year":"2012","unstructured":"Naughton, J. F., Widmer, W. R., Constable, P. D. & Knapp, D. W. Accuracy of three-dimensional and two-dimensional ultrasonography for measurement of tumor volume in dogs with transitional cell carcinoma of the urinary bladder. Am. J. Vet. Res. 73, 1919\u20131924 (2012).","journal-title":"Am. J. Vet. Res."},{"key":"64955_CR48","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1158\/0008-5472.CAN-12-2101","volume":"73","author":"D Dhawan","year":"2013","unstructured":"Dhawan, D. et al. Targeting folate receptors to treat invasive urinary bladder cancer. Cancer Res. 73, 875\u2013884 (2013).","journal-title":"Cancer Res."},{"key":"64955_CR49","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/j.juro.2011.09.010","volume":"187","author":"NM Hahn","year":"2012","unstructured":"Hahn, N. M. et al. Subcutaneous 5-azacitidine treatment of naturally occurring canine urothelial carcinoma: a novel epigenetic approach to human urothelial carcinoma drug development. J. Urol. 187, 302\u2013309 (2012).","journal-title":"J. Urol."},{"key":"64955_CR50","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1111\/vco.12677","volume":"19","author":"AK LeBlanc","year":"2021","unstructured":"LeBlanc, A. K. et al. Veterinary Cooperative Oncology Group-Common Terminology Criteria for Adverse Events (VCOG-CTCAE v2) following investigational therapy in dogs and cats. Vet. Comp. Oncol. 19, 311\u2013352 (2021).","journal-title":"Vet. Comp. Oncol."},{"key":"64955_CR51","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1111\/jvim.15331","volume":"32","author":"MJ Acierno","year":"2018","unstructured":"Acierno, M. J. et al. ACVIM consensus statement: Guidelines for the identification, evaluation, and management of systemic hypertension in dogs and cats. J. Vet. Intern. Med. 32, 1803\u20131822 (2018).","journal-title":"J. Vet. Intern. Med."},{"key":"64955_CR52","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/S0197-2456(98)00037-3","volume":"19","author":"WD Dupont","year":"1998","unstructured":"Dupont, W. D. & Plummer Jr, W. D. Power and sample size calculations for studies involving linear regression. Control. Clin. Trials 19, 589\u2013601 (1998).","journal-title":"Control. Clin. Trials"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-64955-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-64955-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-64955-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T09:02:20Z","timestamp":1788253340000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-64955-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,1]]},"references-count":52,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["64955"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-64955-1","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,1]]},"assertion":[{"value":"21 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"24028"}}